| Ticker Details |
Gilead Sciences, Inc.
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$171.56B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.89 | 1.31%
|
| Avg Daily Range (30 D): |
$2.22 | 1.69%
|
| Avg Daily Range (90 D): |
$1.84 | 1.40%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7.26M |
| Avg Daily Volume (30 D): |
5.1M |
| Avg Daily Volume (90 D): |
4.85M |
| Trade Size |
| Avg Trade Size (Sh.): |
133 |
| Avg Trade Size (Sh.) (30 D): |
56 |
| Avg Trade Size (Sh.) (90 D): |
56 |
| Institutional Trades |
| Total Institutional Trades: |
125,094 |
| Avg Institutional Trade: |
$5.67M |
| Avg Institutional Trade (30 D): |
$17.91M |
| Avg Institutional Trade (90 D): |
$20.4M |
| Avg Institutional Trade Volume: |
.12M |
| Avg Institutional Trades (Per Day): |
21 |
| Market Closing Trades |
| Avg Closing Trade: |
$61.14M |
| Avg Closing Trade (30 D): |
$178.95M |
| Avg Closing Trade (90 D): |
$205.87M |
| Avg Closing Volume: |
870.61K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-2.6
|
$-8.45
|
$1.63
|
|
Diluted EPS
|
$-2.65
|
$-8.45
|
$1.61
|
|
Revenue
|
$30.46B
|
$7.8B
|
$6.96B
|
|
Gross Profit
|
$24.24B
|
$6.22B
|
$5.52B
|
|
Net Income / Loss
|
$-3240M
|
$-10496M
|
$2.02B
|
|
Operating Income / Loss
|
$-2497M
|
$-10394M
|
$2.59B
|
|
Cost of Revenue
|
$6.22B
|
$1.58B
|
$1.45B
|
|
Net Cash Flow
|
$-1964M
|
$-4449M
|
$64M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jan 28, 2013
|
2:1
|
|
Jun 25, 2007
|
2:1
|
|
Sep 07, 2004
|
2:1
|
|
Mar 08, 2002
|
2:1
|
|
Feb 22, 2001
|
2:1
|
|
|
|
